Ilan Chaitowitz, CFA

Ilan has been a Senior Analyst & Portfolio Manager at Nomura Asset Management with over 25 years of experience. He originated and led management of the 5-star Morningstar and ‘5’ Lipper rated, Nomura Global High Conviction Fund – a generalist, 20-stock global equity fund. In January 2022 he stepped down to focus full time on BioZen.
He was previously a Partner at Redburn where his research covered Medical Devices & Services. Prior to that he was a Mergers & Acquisitions analyst at JPMorgan.
He holds a Masters in Clinical Drug Development from Barts & The London School of Medicine, an undergraduate degree in Natural Sciences from Cambridge University, and is a CFA Charterholder.

Anne Marieke has been a senior analyst and portfolio manager in healthcare for over 20 years. She was responsible for up to $1.5bn in different roles working for Threadneedle, Credit Suisse and Amundi. It was during this time that first started working with Ilan Chaitowitz.
In 2018 she moved into strategic communications for early stage SMEs in life-sciences fundraising with Optimum Communications, Global Gene Corp and DEBx Medical.
Anne Marieke is a non executive board member on the EureKING SPAC and is a coach for the Barclays Scale Up programme with Cambridge Judge Business School.
She holds a degree in Biology with focus on Endocrinology from the University of Utrecht and the AoEC coaching certificate for executive coaching.

Brad is Professor and Vice Chair of the Department at the University of Washington School of Medicine and Chief of Medicine of the University of Washington Medical Center, positions that he has held since 2008.
He is a highly experienced clinician and research scientist who has published over 100 peer-reviewed papers. Prof. Anawalt has been regularly recognised for outstanding physician awards.
Brad is an investigator in several ongoing endocrinology trials. He is a member and consultant for the Therapeutics Use Exemption Committee for the United States Anti-Doping Agency and serves as a member of the National Collegiate Athletic Association Committee.
He is a reviewer for the Lancet, Journal of Andrology, Journal of Urology, New England Journal of Medicine, amongst others.

Justin has been an NIHR Professor of Translational Oncology and Professor of Cancer Medicine at Imperial College, publishing over 600 peer-reviewed papers.
His Lancet paper in early 2020 demonstrated that baricitinib would have antiviral and anti-cytokine properties against the Covid-19 virus. He then led many of the global studies leading to its FDA approval 9 months later.
He gained a first class degree in Medicine from Trinity College, Oxford, prior to a residency program at the Johns Hopkins Hospital in Baltimore and training at Barts and the Royal Marsden. His PhD was on the immune response to cancer. He is Editor-in-Chief of Nature's cancer journal, Oncogene.

Justin has been an NIHR Professor of Translational Oncology and Professor of Cancer Medicine at Imperial College, publishing over 600 peer-reviewed papers.
His Lancet paper in early 2020 demonstrated that baricitinib would have antiviral and anti-cytokine properties against the Covid-19 virus. He then led many of the global studies leading to its FDA approval 9 months later.
He gained a first class degree in Medicine from Trinity College, Oxford, prior to a residency program at the Johns Hopkins Hospital in Baltimore and training at Barts and the Royal Marsden. His PhD was on the immune response to cancer. He is Editor-in-Chief of Nature's cancer journal, Oncogene.

FROM GOOD Science TO GOOD HEALTH